Istvan Redei,MD

MD

Director, Hematologic Malignancies and Stem Cell Transplant Program, CTCA Chicago

4.8 (57 Ratings)

11 Reviews
Istvan Redei - Chief, Division of Stem Cell Transplantation, Department of Medical Oncology at Cancer Treatment Centers of America®
quotation

I strive to aggressively fight hematologic cancer and provide my patients with treatment options and hope.

Location
CTCA Chicago
Specialties
Hematologic Oncology
Stem Cell Transplant
Education
Medical school:
Semmelweis Ignác Medical University, Budapest, Hungary
Residency:
Internal Medicine - New York Medical College/Metropolitan Hospital Center
Fellowship:
Hematology/Oncology – Temple University School of Medicine/Fox Chase Cancer Center, Philadelphia, PA
Visiting Fellow – Fred Hutchinson Cancer Research Center, Seattle, WA
Leukemia and Bone Marrow Transplantation – Emory University School of Medicine, Atlanta, GA
Certifications
Hematology - American Board of Internal Medicine

Dr. Istvan Redei is proud to be part of a growing movement toward patient-oriented cancer care. As the leader of the Hematologic Malignancies and Stem Cell Transplant Program, the experienced hematologist-oncologist cares for patients who are fighting hematologic malignancies such as lymphoma and leukemia at Cancer Treatment Centers of America® (CTCA), Chicago.

Prior to joining CTCA®, Dr. Redei served as Director of the Matched Unrelated Donor Transplant Program at the Emory University School of Medicine in Atlanta. He also served as assistant professor of hematology/oncology at the Winship Cancer Center.

Board certified in hematology, Dr. Redei received his medical degree from Semmelweis University in Budapest, Hungary. He then went on to complete his residency at New York Medical College. He completed a fellowship in hematology at Temple University and a fellowship in oncology at Fox Chase Cancer Center, both in Philadelphia.

Patient Ratings
The patient ratings and comments on this page are obtained from an external Press Ganey® outpatient survey provided to all eligible CTCA patients within one to two weeks of their treatment occurrence. Raw data from the answers to the survey questions about our physicians are calculated by Press Ganey into a one- to five- star rating. In the spirit of transparency, all patient comments are posted as written by the patient, whether they are positive or negative. We only exclude comments if they are deemed to be slanderous or libelous, contain profanity or vulgar language, or do not relate to the patient's experience with the doctor involved including comments directed at hospital COVID-19 policies and procedures. As a result, the comments are the views and opinions of the patients surveyed and are not endorsed by, and may not necessarily reflect the opinion of, CTCA.
About our ratings
Aug 3, 2021

5.0

"Exceptional. High degree of trust and confidence."
Jul 19, 2021

5.0

"He is the best!"
Jun 23, 2021

5.0

"I always let everyone I know how wonderful my oncologist'S are and recommend CTCA"
Apr 28, 2021

5.0

"very good doctors"
Mar 31, 2021

5.0

"I have shared all info about your Hospital and my Oncologist to everyone I know. I have even given out the number to people on Social Media that have just found out that they or a loved one has Cancer"
Mar 31, 2021

5.0

"Definite recommendation"
Mar 24, 2021

5.0

"very happy with reidel and dr [...]"
Mar 15, 2021

5.0

"[...] and I recommend to anyone we know for Cancer treatment."
Feb 21, 2021

5.0

"Dr. Redei has been there for me the past [...] years I've survived!"
Feb 10, 2021

5.0

"they are right on top of everything"
Jan 14, 2021

5.0

"They were (are) great. I don't believe I could have received any better treatment anywhere."